secwatch.observer — SEC 8-K summary
======================================

Issuer:     NAVIDEA BIOPHARMACEUTICALS, INC. (—)
CIK:        0000810509
Form:       8-K
Filed at:   2023-06-05T23:59:59+00:00
Accession:  0001437749-23-016520
Event type: other_material
Sentiment:  negative
Materiality: 0.70
Item codes: 3.01, 3.02, 1.01, 5.02, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Navidea receives NYSE American notice over low stock price; board reshuffled
----------------------------------------------------------------------------

- NYSE American gave until Dec 1, 2023 to cure low price via reverse split or sustained price improvement.
- Entered stock exchange with John K. Scott: 990 Series G preferred shares + $68,853 dividends for 11,969 Series J preferred, subject to approval.
- Director Alexander Cappello resigned; Jill Stefanelli, Ph.D. appointed to Board, effective June 1, 2023.
- Company amended Keystone Capital purchase agreement to cap issuance at 19.99% of shares unless price ≥ greater of book or market value.
- Company remains noncompliant with minimum stockholders' equity requirements from prior NYSE American notices.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/810509/000143774923016520/0001437749-23-016520-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/810509/000143774923016520/navb20230602_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-016520

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer